← Back to Clinical Trials
Recruiting NCT06184373

NCT06184373 Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06184373
Status Recruiting
Phase
Sponsor Ohio State University
Condition Gestational Diabetes
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2025-06-06
Primary Completion 2026-05-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 50 Years
Study Type OBSERVATIONAL
Interventions
Continuous glucose monitorOral Glucose Tolerance TestHemoglobin A1c

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2025-06-06 with a primary completion date of 2026-05-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

One third of women with gestational diabetes (GDM), diabetes diagnosed during pregnancy, have abnormal glucose levels within 3 years after pregnancy, but follow up is low. Continuous glucose monitors (CGM), a small sensor inserted under the skin, may be able to screen women with GDM for diabetes risk. The investigators will ask postpartum women to use CGM at 6-8 weeks postpartum and answer surveys about quality of life after wearing the CGM. The investigators will collect data on blood glucose trends for future studies if participants find CGM use acceptable. The investigators hope to learn if CGM could improve postpartum follow up experiences for people with recent GDM.

Eligibility Criteria

Inclusion Criteria: * Women with a viable singleton intrauterine pregnancy * Able to understand the study, and having understood, provide written informed consent in English * Recent pregnancy affected by gestational diabetes Exclusion Criteria: * Pregestational Diabetes (Type I or Type II) * Continued use of diabetes medications (including metformin and insulin) immediately after delivery * Preterm delivery (\< 37 weeks gestation) * Twin or higher order gestation * No access to a smartphone * Unable or unwilling to wear CGM or return for follow up at postpartum mother-infant dyad clinic * Participation in this trial in a prior pregnancy * History of skin allergy to adhesive products or CGM

Contact & Investigator

Central Contact

Rachel Gordon, MD, MPH

✉ rachel.gordon@osumc.edu

📞 614-293-7980

Frequently Asked Questions

Who can join the NCT06184373 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Gestational Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06184373 currently recruiting?

Yes, NCT06184373 is actively recruiting participants. Contact the research team at rachel.gordon@osumc.edu for enrollment information.

Where is the NCT06184373 trial being conducted?

This trial is being conducted at Columbus, United States.

Who is sponsoring the NCT06184373 clinical trial?

NCT06184373 is sponsored by Ohio State University. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology